HRP20000053B1 - Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production - Google Patents

Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production

Info

Publication number
HRP20000053B1
HRP20000053B1 HR20000053A HRP20000053A HRP20000053B1 HR P20000053 B1 HRP20000053 B1 HR P20000053B1 HR 20000053 A HR20000053 A HR 20000053A HR P20000053 A HRP20000053 A HR P20000053A HR P20000053 B1 HRP20000053 B1 HR P20000053B1
Authority
HR
Croatia
Prior art keywords
production
pharmaceutical preparation
oral pharmaceutical
activity compound
antiulcer activity
Prior art date
Application number
HR20000053A
Other languages
English (en)
Inventor
Carlos Picornell Darder
Original Assignee
Liconsa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8300432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20000053(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Liconsa filed Critical Liconsa
Publication of HRP20000053A2 publication Critical patent/HRP20000053A2/hr
Publication of HRP20000053B1 publication Critical patent/HRP20000053B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20000053A 1997-07-31 1998-07-13 Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production HRP20000053B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009701816A ES2137862B1 (es) 1997-07-31 1997-07-31 Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
PCT/ES1998/000204 WO1999006032A2 (es) 1997-07-31 1998-07-13 Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion

Publications (2)

Publication Number Publication Date
HRP20000053A2 HRP20000053A2 (en) 2000-08-31
HRP20000053B1 true HRP20000053B1 (en) 2003-10-31

Family

ID=8300432

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20000053A HRP20000053B1 (en) 1997-07-31 1998-07-13 Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production

Country Status (33)

Country Link
US (1) US20020098242A1 (cs)
EP (1) EP1010423B1 (cs)
JP (1) JP3961217B2 (cs)
KR (1) KR100591488B1 (cs)
AR (1) AR013242A1 (cs)
AT (1) ATE317688T1 (cs)
AU (1) AU751609B2 (cs)
BG (1) BG64967B1 (cs)
CA (1) CA2307037C (cs)
CR (1) CR5826A (cs)
CZ (1) CZ298700B6 (cs)
DE (1) DE69833490T2 (cs)
DK (1) DK1010423T3 (cs)
ES (3) ES2137862B1 (cs)
GT (1) GT199800113A (cs)
HN (1) HN1998000113A (cs)
HR (1) HRP20000053B1 (cs)
HU (1) HU230635B1 (cs)
IL (1) IL134158A (cs)
MY (1) MY121353A (cs)
NO (1) NO20000435L (cs)
NZ (1) NZ502590A (cs)
PA (1) PA8456401A1 (cs)
PE (1) PE105199A1 (cs)
PL (1) PL192961B1 (cs)
PT (1) PT1010423E (cs)
RU (1) RU2207114C2 (cs)
SK (1) SK284892B6 (cs)
TR (1) TR200000264T2 (cs)
TW (1) TW533201B (cs)
UA (1) UA66800C2 (cs)
WO (1) WO1999006032A2 (cs)
ZA (1) ZA986893B (cs)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
FR2793688B1 (fr) * 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6228400B1 (en) * 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
AU2002225763A1 (en) 2000-11-28 2002-06-11 Fmc Corporation Edible pga(propylene glycol alginate) coating composition
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
KR100447085B1 (ko) * 2001-11-08 2004-09-04 바램제약주식회사 마그네슘이온, 칼슘이온 또는 철이온이 고농도로 결합된알긴산의 제조 방법
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
IL161983A0 (en) * 2001-11-21 2005-11-20 Eisai Co Ltd Preparation compositions containing acid-unstable physiologically active compounds, and process for producing the same
US6663888B2 (en) 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
DE60319707T2 (de) 2002-08-02 2008-07-17 Ratiopharm Gmbh Pharmazeutische zusammensetzung enthaltend ein benzimidazol-derivat gemischt mit mikrokristalliner cellulose
EP1556010A4 (en) * 2002-10-31 2007-12-05 Supergen Inc PHARMACEUTICAL FORMULATIONS; WHICH ARE ADDRESSED TO CERTAIN REGIONS OF THE STOMACH-DARM TRAKTS
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
EP2359817B1 (en) * 2003-03-28 2018-01-10 Sigmoid Pharma Limited Solid oral dosage form containing seamless microcapsules
US20050037070A1 (en) * 2003-07-18 2005-02-17 Santarus, Inc. Pharmaceutical formulatins useful for inhibiting acid secretion and methods for making and using them
PT1729797E (pt) 2004-03-22 2008-12-17 Solvay Pharm Gmbh Composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina, contendo tensioactivos
EP1728512A1 (en) * 2004-03-26 2006-12-06 Eisai R&D Management Co., Ltd. Controlled-leaching preparation and process for producing the same
EP1729742A1 (en) * 2004-03-31 2006-12-13 BPSI Holdings, Inc. Enteric coatings for orally ingestible substrates
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
WO2006035417A2 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Dihydropyrimidine microcapsule - formulations
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ728442A (en) 2004-10-21 2018-05-25 Adare Pharmaceuticals Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
BRPI0500586A (pt) * 2005-02-21 2006-10-10 Fundacao Oswaldo Cruz composição farmacêutica, processo para preparar dita composição, uso da respectiva composição no tratamento da imunodeficiência causada por infecção pelo hiv e respectivo método de tratamento
WO2006111980A2 (en) * 2005-04-20 2006-10-26 Ideal Cures Pvt. Ltd. Pva based film coating and film coating compositions
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
CN101233229B (zh) 2005-07-29 2013-05-01 雅培实验室有限公司 制备消毒的胰酶粉末的方法
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
WO2007037259A1 (ja) * 2005-09-29 2007-04-05 Eisai R & D Management Co., Ltd. 生体内での崩壊性を向上させたパルス製剤
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US20100105738A1 (en) * 2006-10-06 2010-04-29 Mitsuru Mizuno Extended release formulations of a proton pump inhibitor
KR101670016B1 (ko) 2007-02-20 2016-10-27 앨러간 파마슈티컬스 인터내셔널 리미티드 안정한 소화 효소 조성물
EP2061440A2 (en) * 2007-04-04 2009-05-27 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
WO2008132707A1 (en) * 2007-04-26 2008-11-06 Sigmoid Pharma Limited Manufacture of multiple minicapsules
CA2685591A1 (en) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Pharmaceutical nimodipine compositions
KR20100097145A (ko) * 2007-11-27 2010-09-02 오하라 야꾸힝 고교 가부시키가이샤 조립물의 제조 방법
WO2009109856A2 (en) 2008-03-07 2009-09-11 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
ES2552723T3 (es) * 2008-05-06 2015-12-01 Dexcel Pharma Technologies Ltd. Formulación de bencimidazol estable
US8840934B2 (en) * 2009-01-02 2014-09-23 Rainbow Pharmaceutical Sa Uses of ammonium chloride
JP5640079B2 (ja) 2009-05-18 2014-12-10 シグモイド・ファーマ・リミテッドＳｉｇｍｏｉｄ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ 油滴含有組成物
WO2011018504A2 (en) 2009-08-12 2011-02-17 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
RU2563623C2 (ru) 2009-12-02 2015-09-20 Апталис Фарма Лимитед Микрокапсулы фексофенадина и содержащие их композиции
US20110217426A1 (en) * 2010-03-04 2011-09-08 Perry Stephen C Enteric coating composition
JP6043929B2 (ja) 2010-10-01 2016-12-14 アラガン ファーマシューティカルズ インターナショナル リミテッド 腸溶コーティングされた低力価パンクレリパーゼ製剤
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
US20120328697A1 (en) * 2011-06-01 2012-12-27 Fmc Corporation Controlled Release Solid Dose Forms
US10016370B2 (en) * 2011-07-14 2018-07-10 Able Cerebral, Llc Composition, device and method for delayed and sustained release of brain energy molecules
US10953025B2 (en) * 2011-07-14 2021-03-23 Able Cerebral, Llc Composition, device and method for delayed and sustained release of brain energy molecules
CA2843556A1 (en) 2011-08-08 2013-02-14 Aptalis Pharma Ltd. Method for dissolution testing of solid compositions containing digestive enzymes
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
EP3639846B1 (en) 2013-08-09 2022-09-28 Allergan Pharmaceuticals International Limited Digestive enzyme composition suitable for enteral administration
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CA2947998A1 (en) 2014-06-19 2015-12-23 Aptalis Pharma Ltd. Methods for removing viral contaminants from pancreatic extracts
MX2014008314A (es) * 2014-07-07 2016-01-06 Andres Abelino Choza Romero Procedimiento para mezclar sustancias, mediante nebulizacion.
TWI535784B (zh) 2014-08-26 2016-06-01 財團法人工業技術研究院 剪切增稠配方、及包含其之複合材料
US10993987B2 (en) 2014-11-07 2021-05-04 Sublimity Therapeutics Limited Compositions comprising Cyclosporin
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CZ2017315A3 (cs) 2017-06-02 2018-12-12 Zentiva, K.S. Dávkovací jednotka s PPI (inhibitory protonové pumpy)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) * 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
SE9002043D0 (sv) * 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
EP0519144B1 (en) * 1991-06-21 1997-08-13 Ilsan Ilac Ve Hammaddeleri Sanayi A.S. New galenic process for omeprazole containing pellets
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
ATE192932T1 (de) * 1993-09-09 2000-06-15 Takeda Chemical Industries Ltd Formulierung enthaltend einen antibakteriellen und einen antiulcus wirkstoff
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms

Also Published As

Publication number Publication date
ES2256943T4 (es) 2007-09-16
SK284892B6 (sk) 2006-02-02
PT1010423E (pt) 2006-06-30
IL134158A (en) 2004-08-31
ES2256943T3 (es) 2006-07-16
UA66800C2 (uk) 2004-06-15
KR100591488B1 (ko) 2006-06-22
EP1010423A2 (en) 2000-06-21
CR5826A (es) 1998-09-28
WO1999006032A3 (es) 1999-08-12
ES2156699A1 (es) 2001-07-01
GT199800113A (es) 2000-01-18
IL134158A0 (en) 2001-04-30
SK1032000A3 (en) 2000-11-07
HU230635B1 (hu) 2017-05-29
CA2307037A1 (en) 1999-02-11
HRP20000053A2 (en) 2000-08-31
PL338613A1 (en) 2000-11-06
NZ502590A (en) 2001-08-31
HN1998000113A (es) 2000-01-06
TW533201B (en) 2003-05-21
DE69833490T2 (de) 2006-10-19
CZ298700B6 (cs) 2007-12-27
DE69833490D1 (de) 2006-04-20
PL192961B1 (pl) 2006-12-29
HUP0002524A2 (hu) 2001-08-28
TR200000264T2 (tr) 2000-09-21
PE105199A1 (es) 1999-11-19
RU2207114C2 (ru) 2003-06-27
US20020098242A1 (en) 2002-07-25
ATE317688T1 (de) 2006-03-15
ES2137862B1 (es) 2000-09-16
EP1010423B1 (en) 2006-02-15
CA2307037C (en) 2006-09-12
AU751609B2 (en) 2002-08-22
JP2001511443A (ja) 2001-08-14
ES2137862A1 (es) 1999-12-16
ZA986893B (en) 1999-01-27
NO20000435L (no) 2000-03-23
BG64967B1 (bg) 2006-11-30
DK1010423T3 (da) 2006-05-22
AU8217398A (en) 1999-02-22
AR013242A1 (es) 2000-12-13
HUP0002524A3 (en) 2002-12-28
CZ2000344A3 (cs) 2000-06-14
JP3961217B2 (ja) 2007-08-22
MY121353A (en) 2006-01-28
NO20000435D0 (no) 2000-01-27
PA8456401A1 (es) 2000-09-29
KR20010022439A (ko) 2001-03-15
ES2156699B1 (es) 2002-03-01
BG104193A (en) 2000-09-29
WO1999006032A2 (es) 1999-02-11

Similar Documents

Publication Publication Date Title
HUP0002524A3 (en) Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production
HUP0201711A3 (en) N-indanyl-benzamide derivatives, method for their production, their use and pharmaceutical preparations containing them
HUP0100431A3 (en) Adamantana derivatives, pharmaceutical compositions comprising them and process for preparing them
HRP20010115B1 (en) Benzocycloheptenes, method for the production thereof, pharmaceutical preparations containing these compounds, and their use for producing medicaments
HUP0000748A3 (en) 4-phenyl-piridine derivatives, process for producing them and pharmaceutical compositions containing them
HUP0003309A3 (en) Imidazolyl-cyclic acetals, process for producing them and pharmaceutical compositions containing the same
HUP0103224A3 (en) Quinoline derivatives, process for producing them and pharmaceutical compositions containing them
HUP0102084A3 (en) Quinoline derivatives, process for producing them and pharmaceutical compositions containing them
HUP0105136A3 (en) Amide derivatives, process for their preparation and medicaments containing them
HUP0103708A3 (en) Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method
HUP9900120A3 (en) Benzosulfone derivatives, process for producing them and pharmaceutical compositions containing them
HUP9802653A3 (en) Substituted imidazolidine derivatives, process for producing them, and pharmaceutical compositions containing them
HUP0003608A3 (en) Tetrahydroisoquinoline derivatives, process for producing them and pharmaceutical compositions containing them
IL136425A0 (en) Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
HUP0203496A3 (en) Novel cyclopropane derivatives, pharmaceutical compositions containing them and method for the production thereof
HUP0002059A3 (en) Immobilized activity stabilized lhrh antagonist complexes, method for the production thereof and pharmaceutical compositions comprising thereof
HUP0100978A3 (en) Benzothiadiazoles and derivatives, process for their preparation and medicaments containing them
HUP0002300A3 (en) Quinoline-4-carboxamide derivatives, process for producing them, pharmaceutical compositions containing them and their use
HUP0001522A3 (en) Benzoimidazole derivatives, process for producing them and pharmaceutical compositions containing them
HUP0105479A3 (en) Betha-alanine derivatives, process for producing them and pharmaceutical compositions containing them
HUP0104620A3 (en) 2-phenylpyran-4-one derivatives, process for their preparation and medicaments containing them
HU9501041D0 (en) Peptide-boronic acid derivatives, process for producing them and pharmaceutical application thereof
ZA988711B (en) New tetracycles, process for their production and pharmaceutical preparations containing these compounds.
HUP0201916A3 (en) Ethanesulfonyl-piperidine derivatives, process for producing them and pharmaceutical compositions containing them
HUP0003766A3 (en) Isoguinolin derivatives, process for producing them and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: LABORATORIOS LICONSA, S.A., ES

ODRP Renewal fee for the maintenance of a patent

Payment date: 20170623

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20180713